{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:58:43Z","timestamp":1792796323957,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejphar.2020.173553","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T11:18:55Z","timestamp":1600255135000},"page":"173553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review"],"prefix":"10.1016","volume":"887","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-7737","authenticated-orcid":false,"given":"Micha\u0142","family":"Otr\u0119ba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7837-9813","authenticated-orcid":false,"given":"Leon","family":"Ko\u015bmider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5221-5765","authenticated-orcid":false,"given":"Anna","family":"Rzepecka-Stojko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173553_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14787210.2019.1635009","article-title":"Broad-spectrum antiviral agents: A crucial pandemic tool","volume":"17","author":"Adalja","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ejphar.2020.173553_bib2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jhep.2019.01.033","article-title":"A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors","volume":"70","author":"Banda","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2020.173553_bib3","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1172\/JCI26032","article-title":"Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor\u2013 viral RNA interactions","volume":"115","author":"Beignon","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2020.173553_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.virol.2010.02.015","article-title":"Ebola virus uses clathrin-mediated endocytosis as an entry pathway","volume":"401","author":"Bhattacharyya","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.ejphar.2020.173553_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004502","article-title":"Coronavirus cell entry occurs through the endo-\/lysosomal pathway in a proteolysis-dependent manner","volume":"10","author":"Burkard","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejphar.2020.173553_bib6","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/AAC.02593-12","article-title":"Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes","volume":"57","author":"Chamoun-Emanuelli","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173553_bib7","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1016\/0006-2952(87)90678-2","article-title":"Effect of chlorpromazine on PZ-peptidase and several other peptidase activities in cloned osteoblastic cells (MC3T3-E1)","volume":"36","author":"Chikuma","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173553_bib8","doi-asserted-by":"crossref","first-page":"10543","DOI":"10.1128\/JVI.78.19.10543-10555.2004","article-title":"Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway","volume":"78","author":"Chu","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2020.173553_bib9","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173553_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1389450119666190920153247","article-title":"Antiviral drug targets of single-stranded RNA viruses causing chronic human diseases","volume":"21","author":"Dinesh","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2020.173553_bib11","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173553_bib12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: Current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2020.173553_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2015.03.005","article-title":"Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules","volume":"118","author":"Ferraris","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173553_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/pathogens8030111","article-title":"Review of emerging Japanese Encephalitis Virus: New aspects and concepts about entry into the brain and inter-cellular spreading","volume":"8","author":"Filgueira","year":"2019","journal-title":"Pathogens"},{"key":"10.1016\/j.ejphar.2020.173553_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015483","article-title":"Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase c epsilon","volume":"5","author":"Filone","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173553_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1073\/pnas.0912966107","article-title":"Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection","volume":"107","author":"Gastaminza","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2020.173553_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000445852","article-title":"Subgroup \u2018assessment of pathogens transmissible by blood\u2019. Human immunodeficiency virus (HIV)","volume":"43","year":"2016","journal-title":"Transfus. Med. Hemotherapy"},{"key":"10.1016\/j.ejphar.2020.173553_bib18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jmv.25031","article-title":"The antimalarial drug amodiaquine possesses anti-ZIKA virus activities","volume":"90","author":"Han","year":"2018","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2020.173553_bib19","doi-asserted-by":"crossref","first-page":"172402","DOI":"10.1016\/j.ejphar.2019.05.031","article-title":"Molecular mechanisms of anti-psychotic drugs for improvement of cancer treatment","volume":"856","author":"Hendouei","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173553_bib20","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.3390\/ijms20215478","article-title":"Emerging highly virulent porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and rational design of live attenuated vaccines","volume":"20","author":"Hou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2020.173553_bib31","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1128\/JVI.00253-07","article-title":"Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted","volume":"81","author":"Inoue","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2020.173553_bib32","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1074\/jbc.RA118.004976","article-title":"Crimean Congo hemorrhagic fever virus nucleocapsid protein harbors distinct RNA binding sites in the stalk and head domains","volume":"294","author":"Jeeva","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2020.173553_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/med.21664","article-title":"Medicinal chemistry strategies toward host targeting antiviral agents","author":"Ji","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2020.173553_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2020.173553_bib35","first-page":"85","article-title":"Ebola virus disease: a literature review","volume":"3","author":"Kimura","year":"2015","journal-title":"J. Coast. Life Med."},{"key":"10.1016\/j.ejphar.2020.173553_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.antiviral.2018.08.013","article-title":"High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system","volume":"158","author":"Lee","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173553_bib37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fmicb.2020.00242","article-title":"Characterization of Zika virus endocytic pathways in human glioblastoma cells","volume":"11","author":"Li","year":"2020","journal-title":"Front. Microbiol."},{"issue":"9","key":"10.1016\/j.ejphar.2020.173553_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007575","article-title":"Chikungunya-attributable deaths: A neglected outcome of a neglected disease","volume":"13","author":"Lima Neto","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejphar.2020.173553_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","article-title":"Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines","volume":"47","author":"Liu","year":"2020","journal-title":"J. Genet. Genomics."},{"key":"10.1016\/j.ejphar.2020.173553_bib40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1128\/AAC.03977-14","article-title":"Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173553_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1996.tb10612.x","article-title":"Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs","volume":"93","author":"Maes","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ejphar.2020.173553_bib42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5530\/jyp.2019.11.26","article-title":"Drug repurposing in antiviral research: A current scenario","volume":"11","author":"Mani","year":"2019","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.ejphar.2020.173553_bib43","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1016\/j.vaccine.2015.08.020","article-title":"Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe","volume":"33","author":"Mansfield","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2020.173553_bib44","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1099\/vir.0.18883-0","article-title":"Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine","volume":"84","author":"Nawa","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejphar.2020.173553_bib45","first-page":"361","article-title":"Middle east respiratory syndrome-coronavirus (MERS-CoV): An updated overview and pharmacotherapeutics","volume":"5","author":"Pillaiyar","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173553_bib46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2020.173553_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028923","article-title":"Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays","volume":"6","author":"Pohjala","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173553_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: A systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173553_bib49","first-page":"S8","article-title":"Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies","volume":"22","author":"Puchades","year":"2018","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.ejphar.2020.173553_bib50","first-page":"1","article-title":"2019 Novel coronavirus (COVID-19) outbreak: A Review of the current literature","volume":"4","author":"Sahin","year":"2020","journal-title":"EJMO"},{"key":"10.1016\/j.ejphar.2020.173553_bib51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5808\/GI.2016.14.3.104","article-title":"Virtual screening for potential inhibitors of NS3 protein of Zika virus","volume":"14","author":"Sahoo","year":"2016","journal-title":"Genomics Inform"},{"key":"10.1016\/j.ejphar.2020.173553_bib52","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejphar.2020.173553_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/infdis\/jiu377","article-title":"Repurposing of prochlorperazine for use against Dengue virus infection","volume":"211","author":"Simanjuntak","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173553_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/v11010059","article-title":"From SARS to MERS, thrusting coronaviruses into the spotlight","volume":"11","author":"Song","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2020.173553_bib55","first-page":"5983","article-title":"Possible biological and clinical applications of phenothiazines","volume":"37","author":"Varga","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2020.173553_bib56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0278-5846(97)00034-1","article-title":"A longitudinal study of cerebrospinal fluid angiotensin-converting enzyme in neuroleptic-treated schizophrenia","volume":"21","author":"Wahlbeck","year":"1997","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2020.173553_bib57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2020.173553_bib58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13567-020-0739-7","article-title":"PEDV enters cells through clathrin-, caveolae-, and lipid raft-mediated endocytosis and traffics via the endo-\/lysosome pathway","volume":"51","author":"Wei","year":"2020","journal-title":"Vet. Res."},{"key":"10.1016\/j.ejphar.2020.173553_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0379-0738(01)00483-2","article-title":"Drug and chemical blood level data 2001","volume":"122","author":"Winek","year":"2001","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.ejphar.2020.173553_bib60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/v10060294","article-title":"The interplay of viral and host factors in chikungunya virus infection: Targets for antiviral strategies","volume":"10","author":"Wong","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2020.173553_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cells8030281","article-title":"Novel falvivirus antiviral that targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer","author":"Yang","year":"2019","journal-title":"Cells"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:45:55Z","timestamp":1757976355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920306452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":51,"alternative-id":["S0014299920306452"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173553","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173553"}}